The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination
Open Access
- 17 May 2022
- Vol. 10 (5), 794
- https://doi.org/10.3390/vaccines10050794
Abstract
The SARS-CoV-2 variant Omicron has spread world-wide and is responsible for rapid increases in infections, including in populations with high vaccination rates. Here, we analysed in the sera of vaccinated individuals the antibody binding to the receptor-binding domain (RBD) of the spike protein and the neutralization of wild-type (WT), Delta (B.1.617.2), and Omicron (B.1.1.529; BA.1) pseudotyped vectors. Although sera from individuals immunized with vector vaccines (Vaxzevria; AZ and COVID-19 Janssen, Ad26.COV2.S; J&J) were able to bind and neutralize WT and Delta, they showed only background levels towards Omicron. In contrast, mRNA (Comirnaty; BNT) or heterologous (AZ/BNT) vaccines induced weak, but detectable responses against Omicron. While RBD-binding antibody levels decreased significantly six months after full vaccination, the SARS-CoV-2 RBD-directed avidity remained constant. However, this still coincided with a significant decrease in neutralization activity against all variants. A third booster vaccination with BNT significantly increased the humoral immune responses against all tested variants, including Omicron. In conclusion, only vaccination schedules that included at least one dose of mRNA vaccine and especially an mRNA booster vaccination induced sufficient antibody levels with neutralization capacity against multiple variants, including Omicron.Funding Information
- Federal Ministry of Health (CHARIS-6a, Varipath 6b)
This publication has 37 references indexed in Scilit:
- Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor populationJCI Insight, 2020
- Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor populationPublished by Cold Spring Harbor Laboratory ,2020
- Convergent antibody responses to SARS-CoV-2 in convalescent individualsNature, 2020
- A serological assay to detect SARS-CoV-2 seroconversion in humansNature Medicine, 2020
- SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test SetupCurrent Protocols in Microbiology, 2020
- Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated With a Candidate CHIKV VaccineThe Journal of Infectious Diseases, 2019
- Establishment of an Alphavirus-Specific Neutralization Assay to Distinguish Infections with Different Members of the Semliki Forest ComplexViruses, 2019
- A neutralization assay for chikungunya virus infections in a multiplex formatJournal of Virological Methods, 2014
- Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63Journal of Virology, 2010
- Modular Synthesis of Heparan Sulfate Oligosaccharides for Structure−Activity Relationship StudiesJournal of the American Chemical Society, 2009